![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, April 30, 2016 2:24:49 PM
Ovarian cancer is the indication that will get K FDA approval, but I believe lung cancer is the indication that will bring K blockbuster status. Consider that:
"The p53 gene is damaged, missing or under-expressed in 42 percent of common cancers and 70 percent of lung cancers."
Further consider that:
It's [p53] by far the most common mutation in cancer. Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute.
http://www.news-medical.net/news/20151121/Crucial-tumor-suppressing-gene-protects-immune-attack-against-lung-cancer.aspx
Adding to the difficulties in treating lung cancer:
The majority of lung cancer patients are diagnosed with advanced disease (stage IIIb/IV). For these patients, conventional treatment options including surgery, chemotherapy, and radiation are unlikely to result in cure, although they may significantly improve survival and provide symptom relief.
http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/lung-cancer
This suggest that most lung cancer patients, when diagnosed, require advanced-combination treatments of drugs and immunotherapies like Opdivo or Keytruda, whose effectiveness is only about 20%. I believe adding Kevetrin to these "combos" will greatly improve the effectiveness of these two immunotherapies and other lung cancer drugs, and will make this indication CTIX's most lucrative.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM